Drug Profile
Research programme: semi synthetic cancer vaccines - Glycovax Pharma
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Glycovax Pharma
- Class Cancer vaccines; Glycoconjugates
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Breast-cancer in Canada (Parenteral)
- 28 Feb 2022 No recent reports of development identified for research development in Breast-cancer(Prevention) in Canada (Parenteral)
- 04 Apr 2018 Glycovax Pharma files for patent protection with the US Patent and Trademarks Office for semi-synthetic cancer vaccine in USA